Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 15/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | TDO2 | P48775 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14112074 | 0.90 | SIGMAR1 (0.50) | SIGMAR1IDO1TDO2ALDH1A1TP53 | |
| SCHEMBL6339199 | 0.85 | IDO1 (0.64) | SIGMAR1IDO1TDO2ALDH1A1TP53 | |
| SCHEMBL9479601 | 0.84 | CYP2D6 (0.54) | SIGMAR1IDO1TDO2ALDH1A1TP53 | |
| SCHEMBL2743258 | 0.82 | SIGMAR1 (0.67) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL3819419 | 0.82 | SIGMAR1 (0.52) | SIGMAR1IDO1TDO2ALDH1A1TP53 | |
| SCHEMBL14112076 | 0.81 | HSD11B1 (0.46) | SIGMAR1IDO1TDO2ALDH1A1TP53 | |
| SCHEMBL6169664 | 0.81 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL8556730 | 0.80 | SIGMAR1 (0.60) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL14154473 | 0.79 | SIGMAR1 (0.52) | SIGMAR1IDO1TDO2ALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL6396217 | 0.79 | SIGMAR1 (0.52) | SIGMAR1IDO1TDO2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180134707-A1 | AZASPIRO[4.5]DECANE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2018-05-17 | — | — | US | disclosed |
| US-9884865-B2 | Azaspiro[4.5] decane derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884865-B2 | Azaspiro[4.5] decane derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9868763-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-01-16 | — | — | US | disclosed |
| US-20170342070-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-9782408-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-20160207923-A1 | AZASPIRO[4.5] DECANE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2016-07-21 | — | — | US | disclosed |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| US-20140315796-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-10-23 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | SIGMAR1 244/4885IDO1 730/4885TDO2 2149/4885 |
| US-20180134707-A1 | AZASPIRO[4.5]DECANE DERIVATIVES AND USE THEREOF | TRPV1, SCN5A, TRPA1 | SIGMAR1 146/4885IDO1 1413/4885TDO2 745/4885 |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885IDO1 4683/4885TDO2 4435/4885 |
| US-20170342070-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | SIGMAR1 3637/4885IDO1 128/4885TDO2 433/4885 |
| US-20140315796-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | SIGMAR1 1537/4885IDO1 3094/4885TDO2 4262/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885IDO1 4683/4885TDO2 4435/4885 |
| US-20160207923-A1 | AZASPIRO[4.5] DECANE DERIVATIVES AND USE THEREOF | TRPV1, SCN1A, SCN5A | SIGMAR1 122/4885IDO1 1281/4885TDO2 818/4885 |
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | SIGMAR1 1623/4885IDO1 1839/4885TDO2 835/4885 |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885IDO1 4683/4885TDO2 4435/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885IDO1 4683/4885TDO2 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.